TrialSignal
Clinical trial intelligence report
A Pilot Study of Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (GRIP-IT PILOT)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT04330625-Jul 28, 2026
NCT ID
NCT04330625
Status
TERMINATED
Phase
PHASE1
Sponsor
Duke University
Executive brief
Investment-Ready Snapshot
A Pilot Study of Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (GRIP-IT PILOT) is a PHASE1 clinical asset sponsored by Duke University in Hyperglycemia Drug Induced. SEO and diligence focus: REMD-477, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04330625
Indication
Hyperglycemia Drug Induced
Modality
protein therapy
Target
REMD-477
Intervention
REMD-477
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.